Atrial natriuretic peptide inhibits the aldosterone response to metoclopramide in patients with glomerular disease and essential hypertension.
1. We examined the effects of metoclopramide (MCP: 10 mg i.v.) on plasma atrial natriuretic peptide (ANP) and aldosterone concentrations (PAC) and the effect of ANP on MCP-induced PAC in four patients with primary glomerular diseases and seven patients with essential hypertension. 2. MCP injection caused no significant changes in plasma ANP. MCP produced a marked increase in PAC without a significant change in plasma renin activity. 3. The increase in PAC induced by MCP injection was markedly attenuated when preceded by the infusion of ANP (25 ng/kg per min). 4. These results suggest that the dopaminergic D2 mechanism is not involved in the regulation of ANP secretion and that ANP modulates the dopaminergic regulation of aldosterone secretion.
Matsuoka
H
H
Second Department of Internal Medicine, University of Tokyo, Japan.
Fukui
K
K
Dan
Y
Y
Ishimitsu
T
T
Hirata
Y
Y
Kimura
K
K
Sugimoto
T
T
Ishii
M
M
Kangawa
K
K
Matsuo
H
H
D000328:Adult; D000450:Aldosterone / Q000378:metabolism*; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000494:pharmacology*; D001794:Blood Pressure; D005260:Female; D005921:Glomerulonephritis / Q000503:physiopathology*; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged
D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D008787:Metoclopramide